<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8045">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862251</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-133</org_study_id>
    <secondary_id>2009_559</secondary_id>
    <nct_id>NCT00862251</nct_id>
  </id_info>
  <brief_title>Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)</brief_title>
  <official_title>A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin Versus Switching to Rosuvastatin or Doubling the Statin Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of switching to a combination tablet
      ezetimibe/simvastatin (10mg/20mg) versus rosuvastatin (10 mg) versus doubling the statin
      dose in those patients who have cardiovascular disease and diabetes mellitus not adequately
      controlled on simvastatin 20 mg or atorvastatin 10 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>In Participants Treated With Simvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Simvastatin</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Participants Treated With Atorvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Atorvastatin</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Switching Treatment to Rosuvastatin</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Participants Treated With Simvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Participants Treated With Atorvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Cholesterol (TC)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in LDL-C/HDL-C Ratio</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in TC/HDL-C Ratio</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Non-HDL-C/HDL-C Ratio</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apolipoprotein B (Apo B)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline Apolipoprotein A-I (Apo A-I)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Apo B/Apo A-I Ratio</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">808</enrollment>
  <condition>Cardiovascular Disorder</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Ezetimibe/simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Doubling statin dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe (+) simvastatin</intervention_name>
    <description>ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.</description>
    <arm_group_label>Ezetimibe/simvastatin</arm_group_label>
    <other_name>Vytorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin 40 mg or atorvastatin 20 mg</intervention_name>
    <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
    <arm_group_label>Doubling statin dose</arm_group_label>
    <other_name>Lipitor, Zocor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin 10 mg or simvastatin 20 mg</intervention_name>
    <description>All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.</description>
    <arm_group_label>Ezetimibe/simvastatin</arm_group_label>
    <arm_group_label>Doubling statin dose</arm_group_label>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Lipitor, Zocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has not taken common statins or ezetimibe within 6 weeks of study screening
             or patient is currently taking a daily dose of the following statins for 6 weeks
             prior to study screening: simvastatin, atorvastatin, pravastatin, fluvastatin,
             ezetimibe, lovastatin, or ezetimibe + fluvastatin

          -  Patient is willing to go on a cholesterol and glucose lowering diet for the duration
             of the study

          -  Patient is willing to remain abstinent or use birth control for the duration of the
             study

          -  Patient has Diabetes Mellitus with cardiovascular disease

        Exclusion Criteria:

          -  Patient has sensitivity to certain common statin drugs

          -  Patient is Asian and would not be able to start taking the higher doses of
             rosuvastatin necessary for the study design

          -  Patient consumes more than 2 alcoholic drinks per day

          -  Patient is pregnant or breast-feeding

          -  Patient has been treated with other investigational drugs within 30 days of first
             visit

          -  Patient is currently on prohibited doses of the following statin drugs: rosuvastatin,
             simvastatin, atorvastatin, and pravastatin

          -  Patient has congestive heart failure

          -  Patient has uncontrolled high blood pressure

          -  Patient has kidney disease

          -  Patient has uncontrolled endocrine or metabolic disease which are known to possibly
             increase blood lipoproteins

          -  Patient has diabetes mellitus that is not well controlled

          -  Patient is human immunodeficiency virus (HIV) positive

          -  Patient is currently taking medications that inhibit Cytochrome P450 3A4 (CYP3A4)

          -  Patient is currently taking therapies that would increase the risk of muscle weakness

          -  Patient has been taking certain over- the-counter lipid-lowering agents within 6
             weeks prior to visit 1

          -  Patient is currently taking psyllium or other fiber-based laxatives
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Egypt</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 12, 2015</lastchanged_date>
  <firstreceived_date>March 12, 2009</firstreceived_date>
  <firstreceived_results_date>February 23, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiovascular disorder</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Rosuvastatin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe/Simvastatin</title>
          <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
        </group>
        <group group_id="P2">
          <title>Doubling Statin Dose</title>
          <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
        </group>
        <group group_id="P3">
          <title>Rosuvastatin</title>
          <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="322"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="324"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="315"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe/Simvastatin</title>
          <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
        </group>
        <group group_id="B2">
          <title>Doubling Statin Dose</title>
          <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
        </group>
        <group group_id="B3">
          <title>Rosuvastatin</title>
          <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="322"/>
                <measurement group_id="B2" value="162"/>
                <measurement group_id="B3" value="324"/>
                <measurement group_id="B4" value="808"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="64.1" spread="8.8"/>
                <measurement group_id="B2" value="64.7" spread="8.3"/>
                <measurement group_id="B3" value="63.6" spread="8.4"/>
                <measurement group_id="B4" value="64.0" spread="8.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="162"/>
                <measurement group_id="B2" value="82"/>
                <measurement group_id="B3" value="142"/>
                <measurement group_id="B4" value="386"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="160"/>
                <measurement group_id="B2" value="80"/>
                <measurement group_id="B3" value="182"/>
                <measurement group_id="B4" value="422"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="159"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-23.13" lower_limit="-25.95" upper_limit="-20.31"/>
                  <measurement group_id="O2" value="-8.37" lower_limit="-12.32" upper_limit="-4.41"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Percent change in least-square means</param_type>
            <param_value>-14.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.61</ci_lower_limit>
            <ci_upper_limit>-9.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Participants Treated With Simvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Simvastatin</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on subpopulation of participants who were previously treated with simvastatin 20 mg and were switched to either Ezetimibe/simvastatin or had simvastatin dose doubled to 40 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Simvastatin Dose</title>
            <description>simvastatin 40 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="158"/>
                  <measurement group_id="O2" value="78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In Participants Treated With Simvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Simvastatin</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-21.59" lower_limit="-25.54" upper_limit="-17.65"/>
                  <measurement group_id="O2" value="-7.98" lower_limit="-13.57" upper_limit="-2.38"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Percent change in Least Square Means</param_type>
            <param_value>-13.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.44</ci_lower_limit>
            <ci_upper_limit>-6.79</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Participants Treated With Atorvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Atorvastatin</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on subpopulation of participants who were previously treated with atorvastatin 10 mg and were switched to either Ezetimibe/simvastatin or had atorvastatin dose doubled to 20 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Atorvastatin Dose</title>
            <description>atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In Participants Treated With Atorvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Atorvastatin</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-24.58" lower_limit="-28.63" upper_limit="-20.53"/>
                  <measurement group_id="O2" value="-8.85" lower_limit="-14.47" upper_limit="-3.23"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal Data Analysis (LDA)</method>
            <param_type>Percent change in least squares mean</param_type>
            <param_value>-15.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.65</ci_lower_limit>
            <ci_upper_limit>-8.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Switching Treatment to Rosuvastatin</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed primarily based upon the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="315"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Switching Treatment to Rosuvastatin</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-23.13" lower_limit="-25.95" upper_limit="-20.31"/>
                  <measurement group_id="O2" value="-19.32" lower_limit="-22.14" upper_limit="-16.51"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.060</p_value>
            <method>Longitudinal Data Analysis</method>
            <param_type>Percent Change in Least Squares Means</param_type>
            <param_value>-3.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.78</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="315"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="171"/>
                  <measurement group_id="O2" value="43"/>
                  <measurement group_id="O3" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.5</ci_lower_limit>
            <ci_upper_limit>6.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Participants Treated With Simvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on subpopulation of participants who were previously treated with simvastatin 20 mg and were switched to either Ezetimibe/simvastatin or had simvastatin dose doubled to 40 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Simvastatin Dose</title>
            <description>simvastatin 40 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="158"/>
                  <measurement group_id="O2" value="78"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In Participants Treated With Simvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="84"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.3</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>In Participants Treated With Atorvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
        <time_frame>Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Analysis performed on subpopulation of participants who were previously treated with atorvastatin 10 mg and were switched to either Ezetimibe/simvastatin or had atorvastatin dose doubled to 20 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Atorvastatin Dose</title>
            <description>atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="156"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>In Participants Treated With Atorvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of &lt; 70 mg/dL (1.81 mmol/L)</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="87"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Cholesterol (TC)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="315"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Total Cholesterol (TC)</title>
            <units>Percent Change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-13.21" spread="17.69" lower_limit="-14.99" upper_limit="-11.43"/>
                  <measurement group_id="O2" value="-4.88" spread="15.14" lower_limit="-7.37" upper_limit="-2.39"/>
                  <measurement group_id="O3" value="-10.58" spread="15.18" lower_limit="-12.36" upper_limit="-8.81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.38</ci_lower_limit>
            <ci_upper_limit>-5.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.039</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.13</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="315"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Triglycerides</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-5.51" lower_limit="-8.75" upper_limit="-2.15"/>
                  <measurement group_id="O2" value="-2.63" lower_limit="-7.23" upper_limit="2.21"/>
                  <measurement group_id="O3" value="-3.35" lower_limit="-6.66" upper_limit="0.08"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.316</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.53</ci_lower_limit>
            <ci_upper_limit>2.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.356</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.75</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="315"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)</title>
            <units>percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.47" lower_limit="-0.27" upper_limit="3.21"/>
                  <measurement group_id="O2" value="1.00" lower_limit="-1.43" upper_limit="3.43"/>
                  <measurement group_id="O3" value="1.99" lower_limit="0.26" upper_limit="3.73"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.756</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.50</ci_lower_limit>
            <ci_upper_limit>3.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.675</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Sqares Mean Difference</param_type>
            <param_value>-0.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.96</ci_lower_limit>
            <ci_upper_limit>1.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="315"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-18.39" lower_limit="-20.90" upper_limit="-15.88"/>
                  <measurement group_id="O2" value="-6.77" lower_limit="-10.29" upper_limit="-3.25"/>
                  <measurement group_id="O3" value="-15.14" lower_limit="-17.72" upper_limit="-12.70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-11.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.93</ci_lower_limit>
            <ci_upper_limit>-7.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.078</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-3.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.71</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in LDL-C/HDL-C Ratio</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="315"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in LDL-C/HDL-C Ratio</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-21.55" lower_limit="-25.09" upper_limit="-18.01"/>
                  <measurement group_id="O2" value="-7.39" lower_limit="-12.34" upper_limit="-2.43"/>
                  <measurement group_id="O3" value="-18.99" lower_limit="-22.52" upper_limit="-15.46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-14.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.23</ci_lower_limit>
            <ci_upper_limit>-8.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.313</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Sqares Mean Difference</param_type>
            <param_value>-2.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.53</ci_lower_limit>
            <ci_upper_limit>2.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in TC/HDL-C Ratio</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="315"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in TC/HDL-C Ratio</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-12.52" lower_limit="-14.83" upper_limit="-10.22"/>
                  <measurement group_id="O2" value="-4.36" lower_limit="-7.58" upper_limit="-1.14"/>
                  <measurement group_id="O3" value="-10.70" lower_limit="-12.99" upper_limit="-8.40"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.10</ci_lower_limit>
            <ci_upper_limit>-4.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.266</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-1.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.05</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Non-HDL-C/HDL-C Ratio</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="314"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="315"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Non-HDL-C/HDL-C Ratio</title>
            <units>percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-16.77" lower_limit="-20.09" upper_limit="-13.45"/>
                  <measurement group_id="O2" value="-5.32" lower_limit="-9.98" upper_limit="-0.66"/>
                  <measurement group_id="O3" value="-14.64" lower_limit="-17.95" upper_limit="-11.32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-11.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.16</ci_lower_limit>
            <ci_upper_limit>-5.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.371</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.81</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apolipoprotein B (Apo B)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="313"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="313"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Apolipoprotein B (Apo B)</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-14.98" lower_limit="-16.99" upper_limit="-12.97"/>
                  <measurement group_id="O2" value="-6.97" lower_limit="-9.78" upper_limit="-4.15"/>
                  <measurement group_id="O3" value="-12.03" lower_limit="-14.05" upper_limit="-10.02"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.46</ci_lower_limit>
            <ci_upper_limit>-4.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.041</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.78</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline Apolipoprotein A-I (Apo A-I)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="313"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="313"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline Apolipoprotein A-I (Apo A-I)</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.64" lower_limit="-0.84" upper_limit="2.11"/>
                  <measurement group_id="O2" value="-0.93" lower_limit="-2.99" upper_limit="1.12"/>
                  <measurement group_id="O3" value="0.86" lower_limit="-0.62" upper_limit="2.34"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.218</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.93</ci_lower_limit>
            <ci_upper_limit>4.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.832</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Apo B/Apo A-I Ratio</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="313"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="313"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in Apo B/Apo A-I Ratio</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-13.67" lower_limit="-16.27" upper_limit="-11.06"/>
                  <measurement group_id="O2" value="-4.75" lower_limit="-8.39" upper_limit="-1.11"/>
                  <measurement group_id="O3" value="-11.14" lower_limit="-13.75" upper_limit="-8.54"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-8.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.36</ci_lower_limit>
            <ci_upper_limit>-4.47</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.175</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.17</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP)</title>
        <time_frame>Baseline and Week 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy data were analyzed using the full analysis set (FAS) population defined as all randomized participants who received at least one dose of blinded study treatment and had baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin</title>
            <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
          </group>
          <group group_id="O2">
            <title>Doubling Statin Dose</title>
            <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rosuvastatin</title>
            <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="313"/>
                  <measurement group_id="O2" value="159"/>
                  <measurement group_id="O3" value="315"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP)</title>
            <units>Percent change</units>
            <param>Least Squares Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-4.42" lower_limit="-13.94" upper_limit="6.15"/>
                  <measurement group_id="O2" value="-1.64" lower_limit="-14.93" upper_limit="13.74"/>
                  <measurement group_id="O3" value="-9.11" lower_limit="-18.13" upper_limit="0.92"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.749</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-2.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.88</ci_lower_limit>
            <ci_upper_limit>14.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.494</p_value>
            <method>Longitudinal data analysis (LDA)</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>4.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.73</ci_lower_limit>
            <ci_upper_limit>18.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All Patients as Treated (APaT) population was used for the analysis of safety data. The APaT population consisted of all randomized patients who received at
least one dose of study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe/Simvastatin</title>
          <description>Ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks</description>
        </group>
        <group group_id="E2">
          <title>Doubling Statin Dose</title>
          <description>simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.</description>
        </group>
        <group group_id="E3">
          <title>Rosuvastatin</title>
          <description>Rosuvastatin 10 mg tablets, taken once daily for six weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="162"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="162"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>An investigator and/or his/her colleagues may publish the results for their study site independently after the multicenter publication, or 24 months after completion of the study, whichever comes first. The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President,Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
